Skip to main content
Premium Trial:

Request an Annual Quote

USPTO to Issue MDRNA Patent on siRNAs Targeting JAM-1 Gene

Premium

MDRNA announced this week that the US Patent and Trademark Office intends to issue the company a patent covering an siRNA directed against the junctional adhesion molecule-1 gene.

"JAM-1 is a tight junction protein that plays a key role in maintaining epithelial and endothelial barrier functions, leukocyte transmigration, and platelet adhesion, and also functions as a pro-inflammatory molecule," the company said.

The intellectual property, US patent application No. 20070253956, specifically claims "the use of antagonists to JAM-1 Claudin-4 and occludin to open tight junctions," according to its abstract. "The antagonists include, by way of example, antibodies and antibody fragments that bind to the proteins and small interfering nucleic acids that down-regulate the mRNA encoding the proteins."

The application was filed by intranasal drug-delivery firm Nastech Pharmaceutical, which later became MDRNA (see RNAi News, 8/7/2008).

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.